GSK_Annual_Report_2021

Notes to the Consolidated Financial Statements for the year ended March 31, 2021 (contd.) Financial Statements GlaxoSmithKline Pharmaceuticals Limited 198 ( ` in lakhs) Year ended March 31, 2021 Year ended March 31, 2020 Consumption of stores and spares 3,10.36 1,08.21 Power, fuel and water 26,07.72 33,36.11 Rent 3,59.34 6,99.22 Rates and taxes 37,88.89 29,95.96 Printing, postage and telephones 9,19.37 11,07.60 Sales training, briefing and conference 91.92 10,51.32 Insurance 5,51.80 4,03.57 Remuneration to auditors : Statutory audit fees 1,00.00 1,00.00 In other capacity in respect of : Tax audit fees 7.00 6.00 Other services 2.50 1.00 Reimbursement of expenses 1.24 3.10 1,10.74 1,10.10 Cost audit fees 5.92 9.77 Corporate social responsibility (Refer Note 36) 7,09.56 10,89.07 Commission to non whole-time Directors 1,43.06 95.21 Directors' sitting fees 49.00 34.50 Legal and professional fees 11,78.50 11,91.74 Miscellaneous 77,08.53 59,08.39 Reimbursement of expenses (net) (Refer Note 35) 49,47.29 30,23.54 576,13.61 630,71.04 NOTE 34: The recurring expenditure on research and development charged off to revenue amounts to ` 1,80.72 lakhs (Previous Year: ` 2,18.02 lakhs) NOTE 35: Reimbursement of expenses (net) are towards the value of costs apportioned, in accordance with the agreements on allocation of expenses with the group companies/ third parties. Note 36 : Expenses towards CSR incurred by the Parent Company Expense towards activities relating to Corporate Social Responsibility in compliance with section 135 of the Companies Act, 2013 is as under: ( ` in lakhs) Year ended March 31, 2021 Year ended March 31, 2020 a) Amount spent (i) Construction/ acquisition of the asset - - (ii) On purposes other than (i) above 10,87.29 11,46.28 Total amount spent 10,87.29 11,46.28 The above includes allocation of ` 54.30 lakhs (Previous Year ` 57.21 lakhs) towards Corporate Social Responsibility which are shown under Employee Benefits Expenses in note 30. (b) Gross amount required to be spent by the Parent Company 10,86.04 11,44.25